LGVN Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -5270.8% compared to Longeveron, Inc.'s net margin of --. Longeveron, Inc.'s return on equity of -122.24% beat CEL-SCI Corp.'s return on equity of -266.61%.

Longeveron, Inc. has a consensus price target of $6.86, signalling upside risk potential of 1168.48%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 857.21%. Given that Longeveron, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Longeveron, Inc. is more attractive than CEL-SCI Corp..

Longeveron, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Longeveron, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Longeveron, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Longeveron, Inc. quarterly revenues are $137K, which are larger than CEL-SCI Corp. quarterly revenues of --. Longeveron, Inc.'s net income of -$7.2M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Longeveron, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Longeveron, Inc. is 5.95x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -5270.8% compared to Longeveron, Inc.'s net margin of -953.4%. Longeveron, Inc.'s return on equity of -122.24% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Longeveron, Inc. has a consensus price target of $6.86, signalling upside risk potential of 1168.48%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1178.88%. Given that IGC Pharma, Inc. has higher upside potential than Longeveron, Inc., analysts believe IGC Pharma, Inc. is more attractive than Longeveron, Inc..

Longeveron, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Longeveron, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Longeveron, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Longeveron, Inc. quarterly revenues are $137K, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Longeveron, Inc.'s net income of -$7.2M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Longeveron, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Longeveron, Inc. is 5.95x versus 22.74x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -5270.8% compared to Longeveron, Inc.'s net margin of -255.85%. Longeveron, Inc.'s return on equity of -122.24% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Longeveron, Inc. has a consensus price target of $6.86, signalling upside risk potential of 1168.48%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Longeveron, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Longeveron, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Longeveron, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Longeveron, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Longeveron, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Longeveron, Inc. quarterly revenues are $137K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Longeveron, Inc.'s net income of -$7.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Longeveron, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Longeveron, Inc. is 5.95x versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -5270.8% compared to Longeveron, Inc.'s net margin of 13.19%. Longeveron, Inc.'s return on equity of -122.24% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Longeveron, Inc. has a consensus price target of $6.86, signalling upside risk potential of 1168.48%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that Longeveron, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Longeveron, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Longeveron, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Longeveron, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Longeveron, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Longeveron, Inc. quarterly revenues are $137K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Longeveron, Inc.'s net income of -$7.2M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Longeveron, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Longeveron, Inc. is 5.95x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.